The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Modecate     2-[4-[3-[2-(trifluoromethyl) phenothiazin...

Synonyms: Moditen-depo, Dapotum D, SureCN41288, Moditen depot, CCRIS 3954, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lyogen


Psychiatry related information on Lyogen


High impact information on Lyogen


Chemical compound and disease context of Lyogen


Biological context of Lyogen


Anatomical context of Lyogen

  • Treatment with a single weekly dose of fluphenazine decanoate (5 mg/kg) for 3 weeks resulted in increased HVA levels in all the above brain regions, cisternal cerebrospinal fluid and plasma [23].
  • This response was not seen following administration of NT into other striatal regions or the substantia nigra and was suppressed by the NT antagonist SR 48692 (100 micrograms/kg i.p.). Vacuous chewing movements were also seen following chronic administration of fluphenazine decanoate [24].
  • The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats [25].
  • These patients, treated with high total doses of different oral neuroleptics and fluphenazine depot, showed some EEG and ECG abnormalities, eye changes, slight leucopenia, a low number of staff nuclei neutrophils and infiltrations at the injection site, but these reactions did not result in any practical handicaps [26].

Associations of Lyogen with other chemical compounds


Gene context of Lyogen


Analytical, diagnostic and therapeutic context of Lyogen


  1. Letter: Parkinsonism induced by fluphenazine decanoate. Lamb, P., Mindham, R.H., Ezzat, M.A. Lancet (1976) [Pubmed]
  2. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Rifkin, A., Quitkin, F., Rabiner, C.J., Klein, D.F. Arch. Gen. Psychiatry (1977) [Pubmed]
  3. Fluphenazine decanoate and tardive dyskinesia. Schiff, A.A. The American journal of psychiatry. (1982) [Pubmed]
  4. A depot neuroleptic withdrawal study. Plasma concentration of fluphenazine and flupenthixol and relapse frequency. Wistedt, B., Jørgensen, A., Wiles, D. Psychopharmacology (Berl.) (1982) [Pubmed]
  5. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. Cookson, J.C., Kennedy, N.M., Gribbon, D. International clinical psychopharmacology. (1986) [Pubmed]
  6. Costs and benefits of two doses of fluphenazine. Marder, S.R., Van Putten, T., Mintz, J., McKenzie, J., Lebell, M., Faltico, G., May, P.R. Arch. Gen. Psychiatry (1984) [Pubmed]
  7. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Carpenter, W.T., Buchanan, R.W., Kirkpatrick, B., Lann, H.D., Breier, A.F., Summerfelt, A.T. The American journal of psychiatry. (1999) [Pubmed]
  8. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions. Devito, R.A., Brink, L., Sloan, C., Jolliff, F. The Journal of clinical psychiatry. (1978) [Pubmed]
  9. Effects of fluphenazine enanthate and fluphenazine decanoate on discriminated avoidance response and water drinking behavior in rats. Kuribara, H., Tadokoro, S. Psychopharmacology (Berl.) (1979) [Pubmed]
  10. Alcohol abuse in chronic schizophrenics: implications for management in the community. Soni, S.D., Brownlee, M. Acta psychiatrica Scandinavica. (1991) [Pubmed]
  11. Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. Schooler, N.R., Keith, S.J., Severe, J.B., Matthews, S.M., Bellack, A.S., Glick, I.D., Hargreaves, W.A., Kane, J.M., Ninan, P.T., Frances, A., Jacobs, M., Lieberman, J.A., Mance, R., Simpson, G.M., Woerner, M.G. Arch. Gen. Psychiatry (1997) [Pubmed]
  12. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. Kane, J., Quitkin, F., Rifkin, A., Klein, D.F. The American journal of psychiatry. (1978) [Pubmed]
  13. Daytime variation in serum prolactin level in patients receiving oral and depot antipsychotic medication. Goode, D.J., Meltzer, H.Y., Fang, V.S. Biol. Psychiatry (1981) [Pubmed]
  14. Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. Simpson, G.M., Yadalam, K.G., Levinson, D.F., Stephanos, M.J., Lo, E.S., Cooper, T.B. Journal of clinical psychopharmacology. (1990) [Pubmed]
  15. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. McKane, J.P., Robinson, A.D., Wiles, D.H., McCreadie, R.G., Stirling, G.S. The British journal of psychiatry : the journal of mental science. (1987) [Pubmed]
  16. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. Schulz, S.C., Thompson, P.A., Jacobs, M., Ninan, P.T., Robinson, D., Weiden, P.J., Yadalam, K., Glick, I.D., Odbert, C.L. The Journal of clinical psychiatry. (1999) [Pubmed]
  17. Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. Marder, S.R., Hawes, E.M., Van Putten, T., Hubbard, J.W., McKay, G., Mintz, J., May, P.R., Midha, K.K. Psychopharmacology (Berl.) (1986) [Pubmed]
  18. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice. Yamada, K., Furukawa, T. Pharmacology (1982) [Pubmed]
  19. Pharmacological treatment of aggressive behavior and emesis in the Cornelia de Lange Syndrome. Andrasik, F., Ollendick, T.H., Turner, S.M., Hughes, J.R. J. Nerv. Ment. Dis. (1979) [Pubmed]
  20. Changing from oral to depot fluphenazine. Yadalam, K.G., Simpson, G.M. The Journal of clinical psychiatry. (1988) [Pubmed]
  21. Systemic relaxin in pregnant pony mares grazed on endophyte-infected fescue: effects of fluphenazine treatment. Ryan, P.L., Bennett-Wimbush, K., Vaala, W.E., Bagnell, C.A. Theriogenology (2001) [Pubmed]
  22. A six-month follow-up of refractory chronic psychotics treated with Haldol-AID. Wouters, J. Acta psychiatrica Belgica. (1978) [Pubmed]
  23. Chronic haloperidol or fluphenazine: effects on dopamine metabolism in brain, cerebrospinal fluid and plasma of Cercopithecus aethiops (vervet monkey). Bacopoulos, N.G., Redmond, D.E., Baulu, J., Roth, R.H. J. Pharmacol. Exp. Ther. (1980) [Pubmed]
  24. Effects of neurotensin in a rodent model of tardive dyskinesia. Stoessl, A.J. Neuropharmacology (1995) [Pubmed]
  25. The roles of depot injection sites and proximal lymph nodes in the presystemic absorption of fluphenazine decanoate and fluphenazine: ex vivo experiments in rats. Luo, J.P., Hubbard, J.W., Midha, K.K. Pharm. Res. (1998) [Pubmed]
  26. Late (4-8 years) outcome of treatment with megadoses of fluphenazine enanthate in drug-refractory schizophrenics. Dencker, S.J., Enoksson, P., Johansson, R., Lundin, L., Malm, U. Acta psychiatrica Scandinavica. (1981) [Pubmed]
  27. Interactions between procyclidine and neuroleptic drugs. Some pharmacological and clinical aspects. Bamrah, J.S., Kumar, V., Krska, J., Soni, S.D. The British journal of psychiatry : the journal of mental science. (1986) [Pubmed]
  28. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients. Iqbal, M.J., Young, M.A., Charles, J., Elgart, B., Von Greiff, H., Simpson, G.M. The Journal of clinical psychiatry. (1978) [Pubmed]
  29. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Viala, A., Ba, B., Durand, A., Gouezo, F., Hou, N., Jørgensen, A. Psychopharmacology (Berl.) (1988) [Pubmed]
  30. A comparative trail of fluphenazine decanoate and flupenthixol decanoate. Haslam, M.T., Bromham, B.M., Schiff, A.A. Acta psychiatrica Scandinavica. (1975) [Pubmed]
  31. Anodic coulometric detection with a glassy carbon electrode in combination with reversed-phase high-performance liquid chromatography. Determination of blood levels of perphenazine and fluphenazine. Tjaden, U.R., Lankelma, J., Poppe, H. J. Chromatogr. (1976) [Pubmed]
  32. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic. Curson, D.A., Barnes, T.R., Bamber, R.W., Platt, S.D., Hirsch, S.R., Duffy, J.C. The British journal of psychiatry : the journal of mental science. (1985) [Pubmed]
  33. Unusual treatment response of a severe dystonia to diphenhydramine. Bailie, G.R., Nelson, M.V., Krenzelok, E.P., Lesar, T. Annals of emergency medicine. (1987) [Pubmed]
  34. Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. Merali, Z., Toth, G. Pharmacol. Biochem. Behav. (1982) [Pubmed]
  35. Thyroid releasing hormone test in schizophrenic patients with post-psychotic depression. Siris, S.G., Frechen, K., Strahan, A., Cutler, J., Owen, K., Alvir, J., McCorry, T. Prog. Neuropsychopharmacol. Biol. Psychiatry (1991) [Pubmed]
  36. Depot fluphenazine decanoate and enanthate for schizophrenia. David, A., Adams, C.E., Eisenbruch, M., Quraishi, S., Rathbone, J. Cochrane database of systematic reviews (Online) (2005) [Pubmed]
  37. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. Inderbitzin, L.B., Lewine, R.R., Scheller-Gilkey, G., Swofford, C.D., Egan, G.J., Gloersen, B.A., Vidanagama, B.P., Waternaux, C. The American journal of psychiatry. (1994) [Pubmed]
  38. Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics. Shenoy, R.S., Sadler, A.G., Goldberg, S.C., Hamer, R.M., Ross, B. Journal of clinical psychopharmacology. (1981) [Pubmed]
  39. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. Brown, W.A., Silver, M.A. Journal of clinical psychopharmacology. (1985) [Pubmed]
  40. Psychiatric disturbance in mentally handicapped patients. A prospective study of current clinical usage of depot fluphenazine in hospitals for the mentally handicapped. Craft, M.J., Schiff, A.A. The British journal of psychiatry : the journal of mental science. (1980) [Pubmed]
WikiGenes - Universities